Vol 1, No 2 (2010)
Review paper
Published online: 2010-05-14
Approved, new antithrombotic agents: rivaroxaban and dabigatran
Hematologia 2010;1(2):151-156.
Abstract
Approved new antithrombotic agents: rivaroxaban and dabigatran etexilate were discussed
with regards of mechanism of activity, absorption, elimination, indications, contra-indications
and results of published phase III clinical trials.
Keywords: rivaroxabandabigatranvenous thromboembolismatrial fibrillation
